Combination photodynamic therapy and intravitreal ranibizumab in neovascular age-related macular degeneration in a north indian population a pilot Study

Retina

Volumn 28, Issue 9, 2008, Pages 1296-1301

  Kumar, Atul ^a,b   Gopalakrishnan, Kiran ^a   Sinha, Subijoy ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b NONE   (India)

Author keywords

Age related macular degeneration (AMD); Choroidal neovascularization; Combination therapy; Intravitreal ranibizumab; Photodynamic therapy; Verteporfin

Indexed keywords

RANIBIZUMAB; VERTEPORFIN; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; PORPHYRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST SENSITIVITY; CONTROLLED STUDY; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; HUMAN; INDIA; INTERVENTION STUDY; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PILOT STUDY; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; SLIT LAMP; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY; VISUAL IMPAIRMENT; INJECTION; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; STATISTICS; VITREOUS BODY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; CONTRAST SENSITIVITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIA; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; PORPHYRINS; PROSPECTIVE STUDIES; RETREATMENT; VISUAL ACUITY; VITREOUS BODY;

EID: 67649221288     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181814482     Document Type: Article

References (19)

1. Vingerling JR, Diclemans IJ, Hofmann A, et al. The prevalence of age related maculopathy in Rotterdam study. Ophthalmology 1995;102:205-210.
2. Nirmalin PK, Katz J, Robin AL, et al. Prevalence of vitreoretinal disorders in a rural population of South India. The Aravind Comprehensive Eye Study. Arch Ophthalmol 2004; 122:581-586.
3. Klein R, Klein BE, Linton KL. Prevalence of age related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99: 933-943.
4. Hussain N, Das T, Khanna R, et al. Verteporfin therapy for neovascular age related macular degeneration in Indian eyes. Jpn J Ophthalmol 2006;50:524-528.
5. Miller JW, Scmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999; 117:1161-1173.
6. Verteporfin in photodynamic therapy study group. Verteporfin therapy of subfoveal choroidal neovascularisation in age-related macular degeneration: two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-560.
7. Brown DM, Kaiser PK, Michels, et al. Ranibizumab versus verteporfin for neovascular age related macular degeneration. N Engl J Med 2006;355:1432-1444.
8. Heier JS, Boyer DS, Gulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 2006;124:1932-1942.
9. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an antivascular endothelial growth factor antigen binding fragment, as therapy for neovascular age related macular degeneration. Retina 2006;26:859-870.
10. Boyer DS, Antoszyk AN, Awh CC, et al. MARINA study group: Sub group analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmol 2007;114:246-252.
11. Kaiser PK. Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in age-related macular degeneration. Curr Med Res Opinion 2007;23:477-487.
12. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-372.
13. Blick SK, Keating GM, Waqstaff AJ: Ranibizumab. Drugs 2007;67:1199-1206.
14. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, ham controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study Year 1. Am J Ophthalmol 2008;145:239-248.
15. Fung AE, Lalwani GA, Rosenfeld PJ, et a1. An optical coherence tomographyguided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
16. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007; 143:679-680.
17. Kumar A, Sinha S, Kumar V. Visual acuity and contrast sensitivity outcomes in Indian eyes undergoing photodynamic therapy with intravitreal injection of triamcinolone acetonide in age related macular degeneration. Indian J Ophthalmol 2007;55:207-211.
18. Hussein N, Das T, Rawal H, Kallukun SB, et al. Combination therapy of intravitreal triamcinolone and photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation. Indian J Ophthalmol 2006;54:247-250.
19. Dhalla MS, Shah GK, Binder KJ, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularisation in age related macular degeneration. Retina 2006;26:988-993.